|Day Low/High||24.46 / 24.50|
|52 Wk Low/High||2.93 / 24.50|
TheStreet highlights 4 stocks pushing the drugs industry higher today.
Phase II HELIX-2 Trial is the Second HCV Clinical Study to Commence Under Collaboration Agreement With Janssen Pharmaceuticals, Inc.
These under-$10 stocks look ready to trade higher from current levels.
Investors in Idenix Pharmaceuticals Inc saw new options begin trading this week, for the July 2014 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Baupost Group, the hedge fund established and managed by Seth Klarman, recently submitted its 13F filing with the Securities and Exchange Commission (SEC) for the third quarter that ended September 30...
Investors in Idenix Pharmaceuticals Inc saw new options begin trading this week, for the December 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IDIX options chain for the new December 21st contracts and identified one put and one call contract of particular interest.
Today's selling in the biotech sector will re-invigorate the debate about whether a bubble is about to pop.
The revolution is here. Twitter's ability to analyze stock-moving news is killing Wall Street's research model.
â¿¿Chris Lau, Kapitall:Â Quarterly earnings caused a spike in two biotechnology firms, but in different directions last week: Dendreon (DNDN) and [...]
These stocks look ready to break out and trade higher from current levels.
Vertex's lead Hep C drug was placed on partial clinical hold by FDA.
These under-$10 stocks look poised to trade higher from current levels.
The most recent short interest data has been released by the NASDAQ for the 06/14/2013 settlement date, which shows a 1,499,919 share increase in total short interest for Idenix Pharmaceuticals Inc , to 14,882,214, an increase of 11.21% since 05/31/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Chris Lau, Kapitall:Â The ongoing decline in the S&P 500 index from its recent peak in May 2013 could be the [...]
Investors considering a purchase of Idenix Pharmaceuticals Inc stock, but cautious about paying the going market price of $4.69/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2015 put at the $3 strike, which has a bid at the time of this writing of 60 cents.
Phase II HELIX-1 Trial is First HCV Clinical Study to Commence Through Collaboration Agreement With Janssen Pharmaceuticals, Inc.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.